Abstract. Placental/umbilical cord blood (PCB) stem cells for transplantation provide a potentially useful alternative for patients who do not have an HLA-matched family or unrelated bone marrow donor. Concerns regarding this source of stem cells include the limited number of stem cells in a PCB unit and the delayed time to platelet.engraftment. Because of the limited number of stem cells, there is a very clear cell dose effect for both success of engraftment and time to engraftment. As a result, many transplant centers will only consider PCB stem cells as a second choice for transplanting adults, despite the very favorable profile of post-transplant graft-versus-host disease (GvHD). This has resulted in considerable interest in the development of ex vivo stem cell expansion strategies. This review outlines the current status of PCB transplant outcomes as well as the status of our understanding of stem cell expansion with the currently available technologies. A stem cell dose-limiting effect on outcome will result in a narrower window of clinical indications for the use of this stem cell source, despite the acknowledged reduction in GvHD. The trade-offs between poor engraftment and reduction in fatal or severe chronic GvHD remain to be quantitated. 
Introduction
Hematopoietic stem cell (HSC) transplantation in the form of bone marrow transplantation (BMT) to treat inherited or acquired hematologic diseases is well established."
Because not all families had an HLA matched related donor when needed, the National Marrow Donor Program (NMDP) was established in the United States in 1986 to provide a registry of vol unteer BM donors. The registry has now grown to more than 3.5 million potential donors and similar registries have been established in many other countries. Never theless, the length of time required to find a suitable donor (median 3.5 months; range 1 month to six years),3 the limited numbers of donors of ethnic minorities, as well as the rigors of the BM donation process and the risk to the donor, have led to studies of alternative HSC sources.
The potential use of placental/umbilical cord blood (PCB) as a source of transplantable HSC was first sug gested by Boyse in 1983, and "proof of principle" was provided by the finding that lethally-irradiated mice could be rescued and hematopoiesis completely recon stituted by transplantation of perinatal blood. 4 In 1988, Gluckman et al. successfully treated a patient with Fanconi anemia by using PCB from the patient's sib ling.' That patient, the first to have received a related PCB stem cell transplantation, remains alive and free of disease to the present.
In addition, mobilization of HSC into the peripheral blood (PB) and their collection by leukapheresis be came feasible and this source of HSC has been used since the late 1980's to reconstitute marrow function after high-dose chemotherapy for solid tumors or hematologic malignancies."
These advances over the past two decades have extended the field of HSC transplantation and now provide treatment options for malignancies, marrow failure syndromes, hereditary immunodeficiency states, inborn errors of metabolism, and certain solid tumors, as well as providing a platform for gene therapy.
Among the various HSC sources for transplantation, PCB offers a number of potential advantages: (1) PCB is a waste product after childbirth and its procurement is relatively easy; (2) the ability to ensure ethnic diver sity and rare HLA constellations among donors; (3) low risk of transmissible infectious diseases; (4) no risk to the donor; (5) no contamination by residual tumor cells.
Analysis of the clinical results in the first 44 patients transplanted with sibling PCB established the fact that PCB contains sufficient numbers of stem and progenitor cells to engraft at least small recipients and that such transplants were associated with a very low risk of acute and chronic graft-versus-host-disease (GvHD).9
As a result of the early success with PCB, programs for the banking of unrelated donor PCB were initiated both in the U. S. and Europe.10. 11 At present, the Pla cental Blood Program at the New York Blood Center, established in 1992, is the largest PCB bank in the world with approximately 11,000 units collected, HLA typed, tested for infectious transmissible diseases and cryopreserved. Such PCB stem cell preparations can be made available rapidly, with some units identified and transplanted within one week after the initial search request. To date, the Placental Blood Program of the New York Blood Center has provided nearly 1000 PCB units for unrelated transplantation (P. Rubinstein, per sonal communication).
PCB Progenitor Cells: In Vitro Properties
PCB, mobilized PB and BM display differences in numbers and phenotypes of stem and progenitor cells as well as differences in their proliferative response to cytokines.12-28 The different characteristics of PCB, BM and mobilized PB may be due to their different ontogenetic stages or to maturation-related differences in the expression of different surface markers. 19-31 Such differences may influence homing and engraft ment potential following transplantation. In contrast to BM and mobilized PB, PCB progenitor cells have: (1) a higher proliferative potential22, 23 reflected by the size of hematopoietic colonies growing in semisolid medium; (2) For both stem cell sources, the largest percentage of all transplants-49% for PCB and 43% for BM-were carried out for treatment of acute leukemia. The second largest category comprised chronic leukemia for BMT (30%) and congenital disorders for PCB transplants (18%). Most (69%) of the PCB transplants were per formed on patients under the age of 10 (and, therefore, with low body weight). The use of PCB transplantation decreased progressively with increasing patient age. In contrast, the use of BMT is evenly distributed through out all age groups (range 17-26%) (M. Horowitz, per sonal communication).
Observation endpoints reported following trans plantation vary widely from several months to several years so that the interpretation of clinical outcomes is difficult, especially for rare diseases with data collected on only a few patients. The comparison of results from recent PCB transplantation studies to historical results with BMT also needs to take into account that stem cell transplantation techniques have been subject to con stant refinement over the past decades and outcomes are heavily influenced by the experience of the trans plant center. Taking this fact into consideration, the precise interpretation of patient outcomes following PCB versus BM transplantation can only be achieved in future trials by matched/paired case-control studies .
The largest study of PCB transplantation from unre lated donors (and comprising most of the PCB trans plants carried out worldwide between August 1992 and January 1998) was reported by Rubinstein et al. 38 The study includes data on 562 patients who were trans planted for a variety of malignant and non-malignant blood disooooots who were transplanted for a variety of malignant and non-malignant blood disorders, genetic diseases and inborn errors of metabolism, as well as hereditary immunodeficiency states. Patients were followed for likelihood of engraft ment, speed of neutrophil and platelet recovery, GvHD, event-free survival, viral infection and, as appropriate, leukemia relapse. The large number of patients in the study, as well as the integration of preliminary data published earlier on smaller patient groups,9, 36, 40 resolved differences in three areas: (1) engraftment dependent on cell dose infused, (2) delayed platelet recovery following PCB transplanta tion, and (3) CMV-antibody status predictive of GvHD and survival. Three months post-transplantation, the overall rate of transplantation-related events was 46% and these events correlated with the recipient's diag nosis, age, number of leukocytes infused, extent of HLA-disparity, and the location of the center (U.S. versus non-U.S.). The number of leukocytes infused (as nucleated cells/kg recipient body weight) was predictive of the speed of both neutrophil and platelet engraft ment. Graft failure was highest in patients with Fanconi anemia, severe aplastic anemia and chronic myeloge nous leukemia.
The class of HLA mismatch and the presence or absence of CMV-antibodies before transplantation were not associated with transplantation-related events. In accordance with other studies, 9, 36, 37, 39, 40 it is gen erally accepted that the degree of GvHD seen with PCB transplantation is less severe than with BMT. Thus, 31% of patients showed no acute GvHD, 47% grade I-II and 22% grade III-IV. In contrast, a simi larly large study of unrelated BMT reported in 1993 by the NMDP gave the probability of severe GvHD (grade III-IV) to be almost 0.5.3 In general, GvHD following PCB transplantation was more prominent in patients>12 years old, with a greater degree of HLA incompatibility, with infection, and in transplant centers outside the U.S. The frequency of acute grade III-IV GvHD in PCB transplantation was lower in patients matched for 6 of 6 HLA antigens than in patients with one or more HLA mismatches, but did not correlate with the degree of HLA mismatch. Of patients who had previously had grade III-IV acute GvHD, 80% developed chronic GvHD; in comparison, only 18% of those patients who did not have severe acute GvHD developed chronic GvHD. The generally reported low incidence of GvHD after PCB transplantation is a major concern in leukemic patients as the absence of GvHD might be associated with the absence of a graft 
Ex Vivo Expansion of Human HSC
Numerous strategies for the expansion of murine and human HSC and progenitor cells have been eported in the past several years and the studies have included PCB, PB and BM cells.14, 51-18 Consistently, the num bers of hematopoietic progenitor cells (CFC of various classes) can be expanded in culture with a variety of cytokines in the presence or absence of serum compo nents and/or stromal feeder layers. 19-62 The use of early-acting cytokines such as Flt-3 ligand, IL-11, IL-3, stem cell factor (SCF), IL-6 and thrombopoietin (Tpo), as opposed to lineage-restricted cytokines such as granulocyte (G)-colony stimulating factor (CSF), GM CSF and eythropoietin (Epo), was hoped to promote expansion of the HSC pool rather than differentiation of progenitor cells into mature cells. Theoretically, ap plication of different cytokines would expand different subsets of HSC and progenitor cells having different functions in the post-transplant period: accelerated neutrophil and platelet recovery, short-term engraft ment (radioprotection) and long-term engraftment (permanent donor-derived reconstitution of hemato poiesis). However, there is growing evidence that, regardless which cytokines are used, ex vivo cell ex pansion conditions largely facilitate the maturation of HSC into lineage-restricted progenitor cel1s62-64 as well as changes in homing features associated with loss of long-term repopulating capacity. 65 It is generally accepted that the function of a stem cell is defined as the ability to produce cells of all myeloid and lymphoid lineages and, following trans plantation, to home to the bone marrow and perma nently establish hematopoiesis. Candidate cells with "stem -cell like" characteristics have been identified by in vitro assays through features that are thought to dis tinguish HSC from progenitor cells: (1) long-term culture-initiating cells (LTC-IC) grown on bone marrow stromal feeder layers with sustained ability to generate more LTC-IC as well as CFC of various types for sev eral weeks; (2) cobblestone area-forming cells that form cell patches with cobblestone morphology on bone marrow stromal feeder layers (the latter are thought to provide stromal niches for HSC homing); (3) high pro liferative potential-CFC forming extremely large colo nies (several thousand cells per colony) in semisolid culture.
While helpful, these in vitro assays should only be considered as surrogate assays for HSC function. As growth characteristics of candidate HSC in vitro might not translate into HSC function in vivo-especially once HSC have been subjected to ex vivo exposure to cytokines-in vivo models to quantitate HSC numbers and monitor HSC function have been established. One recently developed model is the NOD/SCID mouse. 66 This model permits the study of human HSC function in the mouse, where human HSC are transplanted into a severely immunocompromised host with no graft rejec tion. While allowing semiquantitative assessment of primitive normal and leukemic human stem cells (SCID repopulating cells; SRC), the model has several limi tations. First, malignancies of the lymphohematopoietic system and infections following radiation and trans plantation of hematopoietic cells result in a short life span of only several weeks to a few months in these mice, precluding studies of long-term (>4-6 months) engraftment. Second, human HSC function is tested under xenogeneic conditions that don't mirror the homologous post-transplant environment in man or animal. Some investigators try to mitigate these dis advantages by administering human cytokines post transplant or by placing human bone marrow fragments subcutaneously in order to facilitate homing and to support human HSC function in the murine back ground.61. 67 Third, neutrophil and platelet recovery cannot be assessed because the proportion of human cells in circulation is very low (typically <3%) Piacibello et al. carried out extensive studies on the ex vivo expansion of PCB with subsequent transplan tation into NOD/SCID mice.68. 69 Her studies provided evidence that CD34+ cells from PCB can be expanded in vitro for several months in serum-containing cultures. Combinations of early acting cytokines (Flt-3 ligand, IL-6, Tpo, SCF, IL-3) and the absence of stroma were essential. All cultures were supported by the addition of 10% fetal calf serum or 10% pooled normal human serum. After only 2 weeks-and, therefore, from a clinical perspective potentially interesting-Flt-3 ligand and Tpo, in the presence or absence of SCF, expanded not only CFC but also LTC-IC approximately 100-fold, demonstrating not only expansion of committed pro genitor cells but also cells with stem cell-like character istics with sustained proliferation up to 20 weeks . The addition of IL-3 had a detrimental effect on LTC-IC production beyond week 5.
In a follow-up study, stem cell function following expansion was tested in sublethally irradiated NOD/ SCID mice that were injected with either 20,000 uncul tured CD34+ cells or the progeny of 20,000 CD34+ cells that had been expanded for several weeks in the pres ence of combinations of the aforementioned cytokines (Flt-3 ligand and Tpo; SCF, Flt-3 ligand and Tpo; IL-6, SCF, Flt-3 ligand and Tpo). No engraftment was observed with uncultured cells whereas ex vivo expanded cells engrafted nearly all the mice, although to variable degrees. The frequency of SRC in fresh CD34+ PCB cells was found to be 1 in 29,800 whereas , Other studies of ex vivo expansion of human PCB,51, 52, 55, 62, 74-76 have mostly employed early-acting cytokines such as Flt-3 ligand, IL-11, IL-3, Tpo, SCF and IL-6. While there has been amplification of com mitted progenitor cells as well as amplification or maintenance of cells with surrogate in vitro HSC char acteristics, the studies have not assessed stem cell func tion in vivo following expansion. Therefore, the results of these studies must be interpreted cautiously.
Other transplantation models have been developed to better understand HSC engraftment kinetics follow ing ex vivo cell expansion and transplantation including syngeneic mouse transplants that allow a distinction between donor and recipient-derived hematopoiesis. Such models employ mice that are either congenic for the white blood cell marker CD45.1 or CD45.2, or sex markers, and the models were established to be able to determine percent donor engraftment or to quantitate stem cell-like cells. In these models, the stem cell source used for transplantation is mostly BM because of the difficulty obtaining cord or perinatal blood.
Long term HSC function, defined as the ability of a cell to establish and sustain multilineage hematopoiesis for at least 6 months post-transplantation, has been tested mostly in competitive repopulation assays and/or by applying sublethal myeloablative regimens. The injection of sufficient numbers of cells allows for the survival of all animals, and donor chimerism can be followed over time. However, with regard to ex vivo In contrast, McNiece et al. reported significantly accelerated neutrophil recovery in patients treated for breast cancer with high-dose chemotherapy when expanded cells alone or together with uncultured CD34+ cells were infused and compared to historical controls reconstituted with unmanipulated CD34+ cells alone.97 Cell expansion was achieved using SCF, G-CSF and Tpo.
The choice of cytokines and culture conditions may be critical in the different clinical outcomes in such studies. A well recognized advantage in culturing either BM cells or mobilized PB cells before autologous rein fusion for therapy of malignancy is the elimination of contaminating tumor cells.98-l00 In addition to possibly accelerating speed of neutrophil recovery, ex vivo ex pansion provides an environment for efficient purging of tumor cells as these cells have been shown not to be viable under culture conditions fostering hematopoietic cell expansion.
Summary and Future Direction
Most of the animal studies designed to mimic or predict future clinical application of HSC ex vivo expansion strategies (see above) showed a loss of engraftment potential and long-term repopulation ca pacity under the conditions employed. However, once enough cells were transplanted to pass the threshold for survival, the infusion of expanded cells appeared to ac celerate hematopoietic recovery, at least in the murine transplant model. This effect may very well be depen dent on the combination of cytokines used for expan sion. For mobilized PB and BMT, time to neutrophil engraftment is highly correlated with the number of CD34+ cells infused per kg body weight, and for PCB transplantation with the number of nucleated cells and CFC per kg body weight. 38, 41, 42, 44, 45 In the case of PCB, the development of strategies for ex vivo expan sion of HSC and progenitor cells may be beneficial by shortening the time to hematological recovery, thus reducing the likelihood for infection and the need for continued platelet transfusion. For PB or BM, the use of cytokine-expanded cells may be able to reduce the number of leukapheresis collections needed to obtain sufficient numbers of CD34+ cells or the amount of BM harvested from donors, respectively. The modulating effect of the diverse combinations of cytokines on the degree of expansion as well as the impact of ex vivo culture conditions on the engraftment ability and lon gevity of HSC remain to be clarified. For near-term clinical applications, the most promising concept is the expansion of aliquots rather than total grafts. Injection of the expanded aliquot in addition to the conventional graft should provide a sufficient number of unmanipu lated HSC to guarantee long-term engraftment while also providing an increased number of cells capable of accelerating hematopoietic recovery. 
